A breakthrough functional MRI-based 4D video of fetal default mode network activity, created by University of Washington researchers, provides insight on brain development before and after birth, according to a study in Human Brain Mapping. The findings, based on imaging from eight fetuses between 32 and 37 weeks of gestation, suggest the approach could be used to determine brain development differences between preterm and full-term infants and those with neurodevelopmental disorders such as autism and alcohol or drug exposure, researchers said.
A Dutch study in the journal PLOS Medicine found orthostatic hypotension -- the sudden drop in blood pressure when standing up -- was linked to a 15% higher long-term risk of dementia. Researchers, who reviewed 24-year data for over 6,000 patients, said brief episodes of decreased blood flow to the brain caused by orthostatic hypotension may result in hypoxia, which has damaging effects on brain tissue.
A study in JAMA Internal Medicine found that 78 out of every 1,000 nursing home residents with dementia who were hospitalized in 2013 were placed on mechanical ventilators, and the rate had doubled since 2000. The study found 39% of the patients were admitted to an ICU in 2013, compared with 17% in 2000.
Trial results presented at the European Society for Medical Oncology meeting found that patients with squamous cell carcinoma of the head and neck taking Bristol Myers Squibb's Opdivo, or nivolumab, reported stabilized symptoms and function compared with those taking methotrexate, docetaxel or cetuximab.
Siemens Healthineers' expanded version of its xSPECT Quant technology, which allows users of its Symbia Intevo SPECT/CT system to quantify iodine-123, lutetium-177 and indium-111 in addition to technetium-99, will be introduced at the European Association of Nuclear Medicine annual meeting. The company will also showcase its Biograph Horizon PET/CT Flow edition that incorporates FlowMotion technology to allow continuous bed motion.
Clovis Oncology is eyeing FDA approval in 2017 for its ovarian, peritoneal and fallopian tube cancer drug rucaparib after positive Phase II results. Other possible approvals include Array BioPharma's binimetinib for treatment of NRAS-mutant melanoma and Ariad Pharmaceuticals' lung cancer drug brigatinib.
Oncology guidelines that use prognostic scores to assess benefits are needed for chemotherapy at the end of life, writes Dr. Paolo Bossi of the Fondazione IRCCS Istituto Nazionale dei Tumori in Italy. Commenting on data from France that showed 11% of patients received chemo in the last two weeks of life, Bossi said end-of-life discussions are essential and should occur early in the course of patient care.
Policymakers should evaluate the transition from stage 1 to stage 2 meaningful use to help ensure a successful transition to the Merit-based Incentive Payment System, according to a study in the Journal of the American Medical Informatics Association. Researchers also said the CMS should continue setting high expectations for providers, consider how certified EHR technology is used for clinical quality measures reporting and ensure that MACRA measures are based on evidence showing they will boost health outcomes.
Providers should focus on EHR optimization to help them succeed with population health management and quality reporting requirements in value-based care and the Medicare Access and CHIP Reauthorization Act, said Micky Tripathi of the Massachusetts eHealth Collaborative. Tripathi advises providers to use EHR help portals, communicate with a vendor support specialist or turn to Regional Extension Centers for help with optimization.
Please join Dr. David Schuster for this informative webinar -- Thursday, Oct. 20, at 3:00 p.m. ET -- as he presents the current status of fluciclovine PET-CT, the biologic underpinnings of the use of amino acid imaging for prostate cancer, the approach to interpretation, and the results of key clinical trials. Learn more.
Attend the "Professionalism and Communication" webinar, presented by Jay Harolds, M.D., on Tuesday, Nov. 15, at 12:00 p.m. ET. This members-only webinar series is being offered through a joint initiative of ACNM and SNMMI and is complimentary for ACNM and SNMMI members. Space is limited. ACNM members, learn more and register. SNMMI physician/scientist members, learn more and register.
If you would be a real seeker after truth, it is necessary that at least once in your life you doubt, as far as possible, all things.
Rene Descartes, mathematician and philosopher
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at firstname.lastname@example.org.